Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as a solvent for intravenously administered drugs where compatibility has been established.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - glucose monohydrate, quantity: 55 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as a solvent for intravenously administered drugs where compatibility has been established.

Ізраїль - англійська - Ministry of Health

lapidot medical import and marketing ltd - remifentanil as hydrochloride - powder for concentrate for solution for injection / infusion - remifentanil as hydrochloride 1 mg - remifentanil - remifentanil b.braun is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision .remifentanil b.braun is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.

Ізраїль - англійська - Ministry of Health

lapidot medical import and marketing ltd - remifentanil as hydrochloride - powder for concentrate for solution for injection / infusion - remifentanil as hydrochloride 1 mg - remifentanil - remifentanil b.braun is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision .remifentanil b.braun is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.

Ізраїль - англійська - Ministry of Health

lapidot medical import and marketing ltd - remifentanil as hydrochloride - powder for concentrate for solution for injection / infusion - remifentanil as hydrochloride 2 mg - remifentanil - remifentanil b.braun is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision .remifentanil b.braun is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.

Ізраїль - англійська - Ministry of Health

lapidot medical import and marketing ltd - remifentanil as hydrochloride - powder for concentrate for solution for injection / infusion - remifentanil as hydrochloride 2 mg - remifentanil - remifentanil b.braun is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision .remifentanil b.braun is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.

Ізраїль - англійська - Ministry of Health

lapidot medical import and marketing ltd - remifentanil as hydrochloride - powder for concentrate for solution for injection / infusion - remifentanil as hydrochloride 5 mg - remifentanil - remifentanil b.braun is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision .remifentanil b.braun is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.

Ізраїль - англійська - Ministry of Health

lapidot medical import and marketing ltd - remifentanil as hydrochloride - powder for concentrate for solution for injection / infusion - remifentanil as hydrochloride 5 mg - remifentanil - remifentanil b.braun is indicated as an analgesic agent for use during induction and/or maintenance of general anaesthesia under close supervision .remifentanil b.braun is indicated for provision of analgesia and sedation in mechanically ventilated intensive care patients 18 years of age and over.

США - англійська - NLM (National Library of Medicine)

avera mckennan hospital - dexmethylphenidate hydrochloride (unii: 1678ok0e08) (dexmethylphenidate - unii:m32rh9mfgp) - dexmethylphenidate hydrochloride 20 mg - dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients aged 6 years and older. the effectiveness of dexmethylphenidate hydrochloride extended-release capsules in the treatment of adhd in patients aged 6 years and older was established in 2 placebo-controlled studies in patients meeting dsm-iv criteria for adhd [see clinical studies (14) ]. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of atten

США - англійська - NLM (National Library of Medicine)

sandoz inc - dexmethylphenidate hydrochloride (unii: 1678ok0e08) (dexmethylphenidate - unii:m32rh9mfgp) - dexmethylphenidate hydrochloride 5 mg - dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd) [see clinical studies (14)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including dexmethylphenidate hydrochloride extended-release capsules, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for adhd medications at 1-866-961-2388 or visit https://womensmentalhealth.org/adhd-medications/. risk summary dexmethylphenidate is the d-threo enantiomer of racemic methylphenidate. published studies and postmarketing reports on methylphenidate use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there may be risks to the fetus associated with the use of cns stimulants use during pregnancy (see clinical considerations ). embryo-fetal